Twitter
Advertisement

FDA suspends Jaslok’s blood bank licence for 15 days

The FDA has suspended the licence of Jaslok Hospital’s blood bank for 15 days for transfusing blood of an incompatible group into a patient last year.

Latest News
article-main
FacebookTwitterWhatsappLinkedin

The food and drug administration (FDA) has suspended the licence of Jaslok Hospital’s blood bank for 15 days for transfusing blood of an incompatible group into a patient last year.

Deepti Makhijani, 21, who suffered from leukaemia, died last December at the hospital soon after the transfusion.

PR Uttarwar, joint commissioner, FDA, said, “Following a police complaint, we inspected the blood bank and sent them a show-cause notice. We gave the hospital a chance to give their version and waited for their reply. We also spoke to Makhijani’s parents. Last week, we sent them by post a notice of suspension of licence (of the blood bank) for 15 days.”

Makhijani’s family alleged that she died after hospital staff transfused B-positive blood into her, instead of her A-positive blood group, on December 8, 2011. Hospital doctors, however, blamed complete organ failure for the 21-year-old’s death.

Although it has censured the hospital for the wrong blood transfusion, the FDA clarified that Makhijani’s death was not caused by it. “There is no question of the patient dying because of the error, as the blood was transfused only for four to five minutes,” said Uttarwar.

While medical superintendent Dr AH Ganguly claimed as not having got the notice yet, Deepti’s father Narendra said, “I want the doctor who treated Deepti punished as he signed the prescription prior to the transfusion.”

Find your daily dose of news & explainers in your WhatsApp. Stay updated, Stay informed-  Follow DNA on WhatsApp.
Advertisement

Live tv

Advertisement
Advertisement